Calcipotriol HEXAL

Quick links

Choose a section

Quick links to important sections

Advertisements

Calcipotriol HEXAL

Advertisements
Advertisements

Method of action: Antipsoriatic, D-Vitamin-Like

Treatment option: Plaque Psoriasis, Psoriasis

Advertisements

Overview of Calcipotriol HEXAL

Property Description
Active ingredient Calcipotriol (also Calcipotriene)
Form Ointment, Cream, Solution, or Foam (Topical preparations)
Pharmacological class Vitamin D Analog / Antipsoriatic
Origin Synthetic derivative of Vitamin D3
Product Type Single-agent or fixed combination

What Type of Medicine is Calcipotriol HEXAL?

Calcipotriol HEXAL is a specialized, prescription-only dermatological medicine manufactured by HEXAL and strictly intended for topical use on the skin. The core therapeutic substance is the active ingredient, Calcipotriol, which is chemically defined as a synthetic derivative of Vitamin D3. This compound is classified as a highly specific Vitamin D Analog. The compound is engineered to selectively act on skin cells with minimal effect on systemic calcium metabolism, a key differentiator from the natural hormone analog.

Calcipotriol: Composition and Available Forms

The active substance, Calcipotriol Monohydrate, is manufactured in several versatile topical dosage forms to facilitate effective application across various parts of the body, including ointment, cream, solution, and foam. The final product incorporates the active ingredient into a suitable base/vehicle (such as an emollient base). The availability of these different forms allows the product to be tailored for use on both sensitive areas and difficult-to-treat skin areas. Calcipotriol is used both as a single-agent product and in specific fixed combination preparations alongside other complementary active substances.

What is the General Purpose of this Antipsoriatic Agent?

The general purpose of this medication is to help normalize the life cycle of skin cells that are growing too rapidly. Calcipotriol works by binding to receptors within skin cells, which slows the excessive production and promotes the correct differentiation (maturation) of these cells. By targeting this fundamental cellular imbalance, this antipsoriatic agent is clinically recognized for helping to relieve the visible physical characteristics associated with the underlying condition.

Regulatory References

  1. Calcipotriene Topical: MedlinePlus Drug Information
Advertisements

What side effects are possible with Calcipotriol HEXAL?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety restrictions for Calcipotriol, based on government regulatory documentation. Adverse reactions are primarily reported according to frequency and body system.

Frequency-Classified Adverse Reactions

The most frequently reported effects are localized to the skin:

  • Common (may affect up to 1 in 10 people): Skin irritation, itching (pruritus), redness (erythema), dermatitis (including contact dermatitis), rash (including pustular, erythematous, or exfoliative rash), dry skin, burning sensation of the skin, and peeling skin.
  • Uncommon (may affect up to 1 in 100 people): Psoriasis aggravation, facial swelling (oedema), and systemic effects on calcium balance, specifically elevated calcium in the blood (hypercalcaemia) and urine (hypercalciuria).
  • Rare (may affect up to 1 in 1,000 people): Hives (urticaria) and swelling beneath the skin (angioedema).

Systemic Safety Risks and Restrictions

The most clinically significant systemic safety concern is the potential for hypercalcaemia and hypercalciuria, which are directly related to systemic absorption. This risk is specifically increased if the maximum recommended weekly dose is exceeded.

Calcipotriol is contraindicated (must not be used) in patients with:

  • Known disorders of calcium metabolism.
  • Pre-existing hypercalcaemia.
  • Severe impairment of kidney (renal) or liver (hepatic) function.

Additional Safety Considerations:

  • The use of Calcipotriol is generally avoided during pregnancy and lactation due to insufficient data on safety.
  • Treatment should be limited to 30% of the total body surface area maximum. Concomitant use with other products containing calcipotriol or Vitamin D derivatives must be avoided.
  • Caution is required regarding exposure to natural or artificial ultraviolet (UV) light during treatment, as this may increase the risk of side effects.
Advertisements

Overdose and Emergency Response

️ Calcipotriol HEXAL Overdose and When to Seek Help

Calcipotriol is a vitamin D derivative, and excessive topical use can lead to systemic effects. The maximum recommended dose for adults is 100 grams of the ointment per week. Using more than the maximum weekly amount, applying it over very large body surface areas, or using it for an extended duration can result in an overdose.

Overdose primarily manifests as hypercalcemia (elevated calcium levels in the blood), which is reversible upon stopping treatment. The risk of systemic side effects is generally low when the medication is used strictly as prescribed.

Hypercalcemia Symptoms

If you have applied an excessive amount of Calcipotriol HEXAL, or if you begin to experience symptoms consistent with high blood calcium, discontinue use immediately and seek medical advice. Symptoms of hypercalcemia can include:

  • Increased thirst and frequent urination
  • Nausea and vomiting
  • Muscle weakness and fatigue
  • Confusion, discouragement, or headache

When to Seek Emergency Help

Call emergency medical services immediately if you experience signs of a serious allergic reaction, such as:

  • Swelling of the face, lips, tongue, or throat
  • Difficulty breathing or swallowing
  • Severe, rapidly spreading rash
Advertisements

Therapeutic Uses of Calcipotriol HEXAL

Quick Facts: Calcipotriol HEXAL Uses

  • Targeted Condition: Plaque psoriasis.
  • Therapeutic Domain: Dermatological conditions and skin management.
  • Expected Benefit: Helps manage the signs and symptoms of stable plaque psoriasis.

Calcipotriol HEXAL is a topical preparation indicated for the management of plaque psoriasis. This common skin condition may cause raised, red patches covered with silvery-white scales. The application of Calcipotriol is intended to help address the characteristic skin changes associated with the disease.

Its therapeutic action is primarily focused on reducing the excessive growth and proliferation of skin cells (keratinocytes) that occurs in areas affected by psoriasis. By promoting proper cell differentiation, the compound may offer improvement in the appearance and texture of the lesions.

Clinical experience and trials indicate that treatment with Calcipotriol may help in reducing the severity of symptoms for adult patients. The compound may be used as a standalone treatment or in combination with other therapies as advised by a healthcare professional.

Regulatory References

  1. NIH MedlinePlus guidance
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Calcipotriol HEXAL — Official Regulatory Information

The eligibility for Calcipotriol HEXAL is strictly defined by regulatory documents, primarily allowing use for Adults with stable plaque psoriasis. Use in other populations is subject to specific restrictions and contraindications, reflecting the medicine's nature as a Vitamin D analog.


Contraindicated Populations (Absolute Non-Eligibility)

Official labeling strictly prohibits use in the following populations:

  • Patients with hypercalcemia (high blood calcium) or known disorders of calcium metabolism.
  • Patients with evidence of Vitamin D toxicity.
  • Patients with severe renal (kidney) or severe hepatic (liver) impairment.
  • Patients with a known hypersensitivity to calcipotriol or any component.
  • Individuals with guttate, erythrodermic, or pustular psoriasis (non-plaque forms).

Age and Physiological Status Rules

Population Group Eligibility Status (Regulatory Wording)
Children and Adolescents (Under 18) Use is not recommended due to a lack of established long-term safety and efficacy data.
Pregnancy Safety is not established; use is avoided as a precautionary measure.
Lactation (Breastfeeding) Use requires caution; the medicine must not be applied to the breast.
Application Site Application to the face is formally prohibited.

Eligibility is limited by these factors, ensuring the medicine is only used where its safety profile has been appropriately established by regulatory authorities.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Calcipotriol (the active ingredient in Calcipotriol HEXAL) is primarily governed by its pharmacological action as a Vitamin D analogue and its effect on calcium homeostasis. Since it is applied topically, the risk of systemic drug-drug interactions is generally low, but certain combinations require caution or are restricted.


Documented Interaction Domains

Interaction Domain Summary of Constraint
Calcium Homeostasis Agents Products that increase systemic calcium levels, such as systemic Vitamin D products or calcium supplements, must be considered. Concomitant use with these agents carries a risk of an additive pharmacodynamic effect, potentially leading to clinically significant hypercalcaemia.
Other Topical Antipsoriatics Caution is required regarding the combined use of Calcipotriol HEXAL with other topical antipsoriatic therapies applied to the same area of skin at the same time. Simultaneous application has not been officially studied and may affect absorption or local efficacy.

Interaction-Related Restrictions

The official labeling imposes restrictions related to cumulative systemic exposure. A strict accounting of the total maximum weekly dose for all calcipotriol-containing products must be maintained to mitigate the risk of systemic side effects. Additionally, use is restricted in patients with severe renal or hepatic impairment due to the metabolic role these organs play in the systemic processing of Vitamin D analogues.

Advertisements

Mechanism of Action

Targeting the Vitamin D Receptor and Modulating Keratinocyte Signaling

The core mechanism involves Calcipotriol acting as an agonist for the Vitamin D Receptor (VDR) found in skin cells (keratinocytes). This action influences gene expression to reduce the rate of cell division and promote the normal maturation of keratinocytes, thereby modulating cell differentiation and proliferation pathways.

Dampening Local Immune Signals and Inflammation

The VDR is also present in local immune cells (T-lymphocytes). By modulating this receptor, the drug engages mechanisms that decrease the production of certain pro-inflammatory signaling molecules (cytokines). This action decreases the degree of local T-lymphocyte activation, contributing to the decreased activity of the inflammatory cascade. The combined actions produce a system-level physiological modulation that restores cellular balance in the outer skin layers.

Advertisements

Dosage and Administration Information

How to Use Calcipotriol HEXAL

This section outlines the administration and dosing guidelines for topical calcipotriol preparations.


Administration Scope

Instruction Details
Route of administration Topical (Cutaneous) administration only. Not intended for use in the eyes or internally.
Dosing schedule Typically applied once or twice daily. The frequency may be reduced to once daily for maintenance.
Adult Maximum Dose The maximum total dose must not exceed 100 grams of 0.005% calcipotriol ointment per week.
Missed-dose rule If an application is missed, it should be applied as soon as it is remembered, and the regular schedule should then be resumed.

Application and Procedural Structure

The use protocol requires the medicine to be applied as a thin layer to the affected plaques only and gently rubbed in completely. Users must wash their hands thoroughly immediately following application to prevent unintentional transfer to sensitive areas such as the face or eyes.

Population-Specific Limitations

Dose limits are based on age to control the potential for systemic absorption. The maximum weekly dose for adolescents (12–17 years) should not exceed 75 grams, and for children (6–11 years), the limit is 50 grams. Treatment is generally restricted to no more than 30% of the total Body Surface Area (BSA).

These guidelines define the standardized approach to using the medicine.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Calcipotriol HEXAL

Evidence for Use in Plaque Psoriasis

Research on Calcipotriol HEXAL has primarily focused on its use in adults with plaque psoriasis, which was the condition under study. The evidence includes short-term Randomized Controlled Trials (RCTs) and systematic reviews. In these trials, calcipotriol was evaluated against an inactive base cream, exploring short-term symptom patterns and outcomes related to physical discomfort. Researchers used standardized measures like the Psoriasis Area and Severity Index (PASI) and the Physician's Global Assessment (PGA) to collect data on how skin redness, thickness, and scaling evolved.

Analysis of Short-Term Randomized Controlled Trials

Core research studies for calcipotriol monotherapy are typically short-term, with main observation periods lasting around four to eight weeks, primarily in patients with mild to moderate levels of symptom intensity. Studies report patterns related to how lesions were classified by physicians using the PGA scale, and how total disease area and severity were measured by the PASI. Findings contribute to understanding how the key visible characteristics of psoriasis were observed to evolve in the study groups.

Long-Term Studies and Follow-Up

Beyond the core RCTs, Calcipotriol was also observed in extended open-label studies that monitored responses for up to one year. These extended studies were observational, focusing on how symptoms change over time. While findings indicate patterns related to outcomes measured over time, long-term effects are not fully established by the core RCT evidence. Limited information exists for long-term outcomes, and certainty remains low regarding sustained measurements over many years.

Research Evidence in Specific Populations and Gaps

Calcipotriol monotherapy was primarily evaluated in the adult population, including sub-groups of older adults (65 years and over). Data for certain groups remain insufficient. Specifically, there is limited information concerning the use of calcipotriol monotherapy in children and adolescents. Furthermore, the research predominantly focused on individuals with mild to moderate plaque psoriasis, meaning results apply only to the populations studied. Comparative evidence against some other therapies is limited, and research does not determine whether an individual will respond similarly to the group patterns observed in the studies.

Key Studies & References

  1. PUBLIC ASSESSMENT REPORT of the Medicines Evaluation Board in the Netherlands Calcipotriol 0.05 mg/g, ointment
  2. Management of psoriasis (South & West Devon Formulary - Clinical Guidance)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Calcipotriol HEXAL (FAQ)


Q: Is Calcipotriol HEXAL the same as Dovonex?

A: Calcipotriol is the active ingredient in Calcipotriol HEXAL. Dovonex (or Daivonex) is an older brand name for products containing the exact same active ingredient, calcipotriol. Both products contain the same medication, but are manufactured and marketed under different names.


Q: Does Calcipotriol HEXAL cause skin thinning like some steroid creams?

A: Calcipotriol monotherapy is a Vitamin D derivative, not a steroid. While some combination products contain a corticosteroid which can cause skin thinning (atrophy), calcipotriol by itself does not list skin atrophy as a common side effect in official regulatory documents. Information regarding long-term skin changes should be sought from a healthcare professional.


Q: How quickly does Calcipotriol HEXAL start to work for psoriasis?

A: According to official patient information and clinical trial summaries, some initial improvement may be observed after approximately two weeks of treatment. The maximum effect in clinical studies has generally been observed within an eight-to-twelve week period.


Q: Are there any long-term side effects of using Calcipotriol HEXAL?

A: Core randomized trials typically evaluate safety over short periods (4 to 8 weeks). Long-term systemic safety concerns are primarily focused on the risk of elevated blood calcium (hypercalcaemia) if the maximum allowed weekly dose is exceeded. In many cases, treatment is primarily evaluated for short periods, and its continuation beyond clearance is typically determined by a healthcare professional.


Q: What is the difference between Calcipotriol and Calcitriol?

A: Calcipotriol is a synthetic derivative, meaning it is a man-made version of Vitamin D3, whereas Calcitriol is the active form naturally produced in the body. Pharmacological studies indicate that Calcipotriol acts on skin cell receptors with a lower systemic effect on calcium levels compared to Calcitriol.


Q: Is it normal to feel a slight burning sensation when first applying Calcipotriol HEXAL?

A: Yes, a burning sensation or local skin irritation at the application site is listed as a common adverse reaction in regulatory documents, meaning it may affect up to 1 in 10 people. These sensations are often mild and may be temporary, especially during the initial phase of treatment.


Q: What is the main purpose of the active ingredient, calcipotriol?

A: The general purpose is to help normalize the life cycle of skin cells (keratinocytes) that are growing too rapidly. The goal is to slow down the excessive production and promote the correct maturation of the skin cells, thereby addressing the underlying cellular imbalance in psoriasis.


Q: Does Calcipotriol HEXAL make your skin more sensitive to the sun?

A: Official regulatory guidance advises patients to avoid excessive exposure of the treated skin areas to natural or artificial ultraviolet (UV) light, including tanning beds. Patients are cautioned against excessive exposure because the medicine may increase the risk of side effects from UV light exposure.


Q: Can I apply moisturizer before or after Calcipotriol HEXAL?

A: While the order is not always strictly defined in regulatory documents for the monotherapy, where guidance on application order is provided, it often suggests allowing the moisturizer to fully absorb into the skin first before applying the calcipotriol product.


Q: How is Calcipotriol HEXAL different from other psoriasis treatments?

A: Its primary distinction lies in its classification as an Antipsoriatic agent and a Vitamin D Analog, working by modulating the life cycle and growth of skin cells. This mechanism is distinct from classes like topical corticosteroids or coal tar preparations.


Q: Why do some people experience itching after using Calcipotriol HEXAL?

A: Itching (pruritus) is classified as a common local adverse reaction in clinical studies. While regulatory documents simply list this as an expected effect, the sensation is thought to be related to local skin irritation caused by the medicine.


Q: Can Calcipotriol HEXAL be used during pregnancy or breastfeeding?

A: Official labeling advises that use during pregnancy is generally avoided due to a lack of established safety data. During lactation, use requires caution, and official product information warns that the medicine should not be applied to the breast.


Q: Can Calcipotriol HEXAL be used together with phototherapy (light treatment)?

A: Regulatory documents advise patients to avoid excessive exposure to artificial UV light, including medical phototherapy, unless specific instructions are given by a qualified healthcare professional. This precaution is in place because calcipotriol may increase the risk of side effects from UV exposure.


Q: Can Calcipotriol HEXAL be used in combination with corticosteroid ointments?

A: Caution is advised regarding the combined use of Calcipotriol HEXAL with any other topical antipsoriatic treatments. While fixed-combination products are available, use of two separate products should be undertaken only under the supervision of a healthcare professional.


Q: What are the signs of an allergic reaction to Calcipotriol HEXAL?

A: Signs of a serious allergic reaction (hypersensitivity) can include skin reactions that spread beyond the application site, such as hives (urticaria), and swelling of the face, lips, tongue, or throat (angioedema). These are listed as uncommon or rare side effects.


Q: How does Calcipotriol HEXAL affect the turnover of skin cells?

A: Calcipotriol acts on the Vitamin D Receptor in the skin to help slow down the accelerated production of skin cells (proliferation) and promotes their normal maturation (differentiation). This action works to normalize the cell turnover that is excessive in psoriasis.


Q: Are there different strengths of Calcipotriol HEXAL available?

A: Calcipotriol monotherapy is typically supplied as a 0.005% concentration in its various topical forms (ointment, cream, solution). Specific combination products containing calcipotriol alongside other active ingredients may be available at different concentrations.


Q: Does Calcipotriol HEXAL stain clothing or bedding?

A: Official regulatory documents do not strictly address cosmetic concerns, but patient information for some oilier topical formulations, such as the ointment, may note that they have the potential to stain clothing or bedding.


Q: Can Calcipotriol HEXAL be used for inverse psoriasis?

A: The drug is officially indicated for the treatment of plaque psoriasis. It is often contraindicated for other forms (e.g., guttate, pustular, erythrodermic psoriasis). While the drug is primarily indicated for plaque psoriasis, application to skin folds like those affected by inverse psoriasis may increase systemic absorption, which is a key safety consideration for the medication.


Q: Does Calcipotriol HEXAL interfere with blood tests?

A: Since the medicine is a Vitamin D derivative, it can transiently elevate serum calcium levels, which are measured by a blood test. For this reason, doctors may monitor a patient's calcium levels and kidney function during the course of treatment.


Q: How can I minimize the risk of irritation when using Calcipotriol HEXAL?

A: Official guidance to reduce irritation includes ensuring the medicine is applied only as a thin layer to the affected plaques and is not applied to the face, eyes, or surrounding healthy skin. If excessive irritation develops, discontinuation of the product may be necessary.

Advertisements

How should Calcipotriol HEXAL be stored and disposed of?

How to Store and Dispose of Calcipotriol

Storage and disposal of Calcipotriol topical preparations must strictly follow the conditions specified in the official regulatory labeling.

Storage Conditions

Requirement Specification
Temperature Store at controlled room temperature, between 15°C and 25°C (59°F and 77°F).
Protection Keep tightly closed in the original container, away from light, moisture, and excess heat.
Prohibition The product must not be frozen.
Child Safety Keep the medicine out of the sight and reach of children.

Stability and Disposal

Certain formulations have a defined in-use shelf-life of six months after the initial opening of the container. Any unused medicinal product or waste material must be disposed of in accordance with local requirements and is not to be discarded via household wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Calcipotriol HEXAL found in:

A-Z Index: